RIGARDY MUNOZ: Open Payments
NPI 1427092972 · WILMINGTON, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$847 in 32 payments from 13 companies in 2025. Trend: 2023 $846 · 2024 $524 · 2025 $847
Food & beverage: $847
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $217 |
| Supernus Pharmaceuticals, Inc. | 2 | $129 |
| Bausch Health US, LLC | 4 | $85 |
| Teva Pharmaceuticals USA, Inc. | 4 | $83 |
| Neurocrine BioSciences, Inc. | 3 | $76 |
| Otsuka America Pharmaceutical, Inc. | 3 | $61 |
| Alkermes, Inc. | 3 | $52 |
| E.R. Squibb & Sons, L.L.C. | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Lundbeck LLC | 1 | $24 |
Products named: CAPLYTA, Qelbree, APLENZIN, REXULTI, UZEDY, INGREZZA, ARISTADA, COBENFY.
Industry payments across NC — which companies pay providers there.
